Dechra Introduces First FDA-Approved Oral Treatment for Canine Lymphoma

Dechra Launches Revolutionary Treatment for Canine Lymphoma

In a groundbreaking development for veterinary medicine, Dechra, a prominent name in specialty veterinary care, has launched Laverdia® (verdinexor tablets). This is the first-ever FDA-approved oral treatment specifically designed for dogs diagnosed with lymphoma. Approximately 20% of dogs suffering from this prevalent form of cancer receive chemotherapy, highlighting a critical need for accessible treatment options. With Laverdia®, both veterinary teams and pet owners can initiate care from the very first day after diagnosis, changing the landscape of lymphoma treatment for canines.

Understanding Canine Lymphoma and Treatment Gaps

Lymphoma is among the most frequently diagnosed cancers in dogs. Many pet owners are left with limited choices at the time of diagnosis, often feeling overwhelmed by the treatment options available. Traditional chemotherapy may not be feasible for all families due to its risks and side effects, which has resulted in many dogs not receiving adequate treatment. Laverdia® aims to bridge this gap by being an accessible at-home oral treatment that pet owners can administer right after diagnosis.

Laverdia®: A New Era of Treatment

Dr. Craig A. Clifford, a veterinary oncology expert at BluePearl in Malvern, PA, emphasizes the importance of Laverdia® as it allows more dogs to receive meaningful treatment. The drug is lauded not only for its ability to potentially help dogs whose lymphoma hasn't responded to standard therapies but also for catering to pet owners looking for a gentler treatment approach focused on quality of life. This powerful oral treatment can be used right after a lymphoma diagnosis, between chemotherapy sessions, or when conventional therapies are not the preferred option by the pet owner.

Dr. Tara Bidgood, VP of Professional Services and Medical Affairs at Dechra, also highlighted how several families can now consider additional options through their veterinarians, addressing a critical need during challenging times.

Practical Benefits of Laverdia®

Laverdia® stands out as it offers flexibility in managing canine lymphoma. As an oral therapy, it is designed to be easy for pet owners to administer at home and comes with different dosing options suitable for various dog sizes. This pharmaceutical breakthrough enables veterinary care teams to respond quickly to a diagnosis, empowering families to make informed decisions about their pets’ care while prioritizing their well-being.

Dr. Laura Olsen, President and CMO of Dechra North America, expressed her enthusiasm for Laverdia®, stating that it represents a significant advancement in canine lymphoma management. The combination of FDA approval, the convenience of home administration, and professional support are crucial for guiding families through their pets’ cancer journeys.

Feature Highlights of Laverdia®

Laverdia® (verdinexor) boasts a targeted mechanism of action that can effectively slow down disease progression while minimizing harm to healthy cells. Clinical studies have shown its effectiveness in treating both B-cell and T-cell lymphoma types, making it a versatile option for veterinarians.

Furthermore, the treatment contributes to increasing the number of meaningful treatment days for pets, a vital aspect for families hoping to maximize the time they spend with their beloved companions.

As with all medications, Laverdia® is not without potential side effects. It is essential for pet owners to monitor their dogs closely, being aware of common adverse reactions that may arise during treatment. Specific care guidelines will be provided, ensuring safe use within homes.

Conclusion

The introduction of Laverdia® marks a pivotal moment in veterinary oncology, promising new hope for dogs diagnosed with lymphoma. Dechra continues to be at the forefront of providing innovative solutions in veterinary medicine, further enhancing the lives of pets and the families who care for them. For more information about Laverdia®, pet owners and veterinarians can visit Laverdia.com. This significant advancement underscores the importance of timely intervention in canine lymphoma care and paves the way for greater support, understanding, and healing in the pet community.